Legal Representation
Attorney
Brent D. Sokol
USPTO Deadlines
Next Deadline
90 days remaining
NOA E-Mailed - SOU Required
Due Date
October 22, 2025
Extension Available
Until April 22, 2026
Application History
14 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 22, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 25, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 25, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 19, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 3, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 9, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 9, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 9, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 10, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 10, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 10, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 18, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 15, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 4, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific research services in the nature of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development including companion diagnostics development and complementary diagnostics development; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics including companion diagnostics development and complementary diagnostics development as well as for predicting, measuring or evaluating the performance of the diagnostics; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment including clinical trials as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; Scientific research services in the nature of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development including companion diagnostics development and complementary diagnostics development
Additional Information
Pseudo Mark
MIRADOR THREE HUNDRED SIXTY
Pseudo Mark
MIRADOR THREE SIX ZERO
Pseudo Mark
MIRADOR THREE SIXTY
Classification
International Classes
042